ACHV — Q2 2026 Financial Report Analysis

Achieve Life Sciences' second quarter of 2026 was defined by two events that pull in opposite directions. In June the U.S. Food and Drug Administration (FDA) declined to approve cytisinicline, the company's only drug candidate, for smoking cessation — not because of any problem with the drug's safety or effectiveness, but because of manufacturing observations at a contract manufacturer's plant and product labeling that wasn't finished by the June 20, 2026 decision date. Two months earlier, an April private placement had brought in about $168.2 million, leaving the company with $187.3 million in cash and investments, roughly five times what it held at the end of 2025. The reported net loss of $74.8 million looks alarming, but about $57.5 million of it is accounting for warrants sold in that financing rather than money spent.

At a glance

• $187.3 million in cash, cash equivalents and marketable securities at June 30, up from $36.4 million at December 31, 2025. That is the money that has to carry the company through an FDA resubmission and, if approved, a U.S. launch.
• $17.7 million of operating cash burn in the first half, down from $20.2 million a year earlier. At that pace the cash pile is large relative to spending, though launch costs will raise the burn if the drug is approved.
• NDA resubmission planned for Q4 2026, potential approval in the first half of 2027. The company has moved finished-product manufacturing to Adare Pharma Solutions in Vandalia, Ohio, and will name Adare in the refiled application.

What happened with the FDA

A New Drug Application (NDA) is the formal request to the FDA to sell a new medicine in the U.S. The FDA accepted Achieve's NDA in September 2025 with a target decision date of June 20, 2026. In June it issued a Complete Response Letter (CRL) — a rejection that lists what must be fixed before the application can be approved.

According to the 10-Q, the CRL cited two things: "outstanding manufacturing-related observations from a current Good Manufacturing Practice... inspection of a third-party manufacturing facility" and "final product labeling that was not completed by the FDA's action date." The company states that "the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline." The manufacturer in question had an FDA inspection unrelated to Achieve, received an "Official Action Indicated" classification and a warning letter, and the filing says those observations "relate to general cGMP matters at the facility and are not specific to cytisinicline."

Achieve's fix is to switch manufacturers. It has completed the analytical method transfer (moving its product-testing procedures) to Adare, made a first engineering batch there and qualified all testing procedures at the site. Management plans to resubmit in the fourth quarter of 2026 and anticipates "the potential approval of cytisinicline for smoking cessation in the first half of 2027, followed by U.S. commercial launch."

A second, separate path exists for vaping cessation: in October 2025 the FDA gave cytisinicline for nicotine e-cigarette cessation a Commissioner's National Priority Voucher, under which the FDA aims to decide within one to two months of receiving a complete application. The 10-Q does not give a filing date for that indication.

The numbers

Achieve has no product revenue — it has never sold a product — so there is no revenue or operating margin to report. The meaningful figures are spending, the net loss and cash.

Why research spending fell: R&D dropped mainly because clinical trial costs fell by $3.2 million in the quarter, as the ORCA-OL open-label safety trial finished in September 2025. Stock-based compensation in R&D was also $0.3 million lower. Partly offsetting that, manufacturing and supply-chain costs rose $0.4 million, which the filing ties to launch preparation — buying raw cytisinicline (expensed as R&D because the drug isn't approved yet), the method transfer to Adare and the Adare engineering batch.

Why overhead more than doubled: G&A rose by $8.7 million. The 10-Q attributes most of it to $7.7 million of higher employee expenses "associated with increased stock-based compensation and severance expenses" — the quarter included a CEO change, with Andrew D. Goldberg, M.D. appointed CEO effective April 18, 2026 alongside the financing, and a separation agreement with former CEO Richard Stewart dated May 8, 2026. Launch-preparation costs added another $0.4 million.

What the headline numbers hide

Most of the loss is warrant accounting, not cash. Investors in the April financing received, alongside each share, a warrant — the right to buy another share later at $3.51. Because these warrants are recorded as a liability rather than equity, the company must re-value them every quarter and run any increase through the income statement. Three warrant items hit Q2:

Strip those out and the Q2 loss would have been about $17.3 million versus $12.7 million a year earlier (our arithmetic from the income statement, not a company-reported figure) — a 36% increase driven by the severance and stock-compensation jump in G&A. None of the $57.5 million left the bank; the warrant charges are added back in the cash flow statement.

The balance sheet looks upside down for the same reason. Stockholders' equity is -$14.7 million and working capital (current assets minus current liabilities) is -$9.4 million, even though the company holds $187.3 million of cash and securities. That is because the $183.4 million of warrant and pre-funded warrant liabilities sit in current liabilities. Excluding them, current liabilities would be about $14.3 million against $188.3 million of current assets. The warrants would only ever be settled by issuing shares, not by paying cash out — if exercised, they bring cash in (49.5 million warrants at $3.51 would be about $174 million, our arithmetic). Under their terms they expire 20 business days after the company announces FDA approval, so exercise would be tied to that event.

One reason the warrants may be a liability has since changed. The warrant terms say holders cannot exercise if the company lacks enough authorized, unissued shares; at June 30 Achieve had 102.7 million shares outstanding against 150 million authorized. On July 2, 2026 stockholders approved raising the limit to 300 million shares (effective July 6). The 10-Q does not say whether this changes the warrants' accounting treatment, so whether the quarterly re-valuation swings continue is something to check in the Q3 filing.

Per-share figures are diluted heavily. Weighted average shares nearly tripled to 93.5 million, so the loss per share (-$0.80) grew less than the dollar loss. Counting the 49.5 million new warrants and the warrants from the June 2025 offering, future share counts can rise substantially further.

Cash burn is steadier than the income statement suggests. First-half operating cash use of $17.7 million was lower than last year's $20.2 million, which the filing explains by 2025 having included payment of 2024 bonuses and upfront launch-preparation payments, partly offset by severance paid in 2026. Stock-based compensation, which is non-cash, was $6.3 million in the half versus $5.1 million.

Other obligations are small but real. The company owes $15.0 million on a convertible term loan maturing June 1, 2028; it was interest-only through June 30, 2026, and $7.5 million is now classified as due within a year. A $1.4 million contingent payment to Sopharma becomes due on approval. And in July 2026 Sopharma — which licenses cytisinicline data, patent rights and the Tabex trademark to Achieve — filed an arbitration demand alleging Achieve breached their supply agreement by using other manufacturers; Achieve disputes the claim.

Takeaway: Achieve's Q2 loss is mostly a paper loss from re-valuing warrants; the facts that matter are that the FDA's rejection was about a contract manufacturer rather than the drug itself, and that the April raise left $187.3 million — far more than the $17.7 million the company burned in the first half — to fund a Q4 2026 resubmission and a possible 2027 launch.

What to watch next

• The Q4 2026 resubmission. Timing depends on Adare being ready for FDA review; the company has completed an engineering batch and qualified testing, but has not said when commercial-scale validation batches will be done. Management's own target is potential approval in the first half of 2027.
• Cash runway. The 10-Q does not give a runway estimate; it says management believes the company can meet its obligations over the next 12 months but will depend on raising more money to finish development and commercialize. At the first half's burn rate, $187.3 million would last several years, but that rate will not hold: the company is building a commercial team (market access, medical education, trade) and evaluating field sales reps, so spending should step up ahead of any launch. The warrants offer a potential source of about $174 million if approval comes and holders exercise.
• The vaping indication. With a national priority voucher promising a one-to-two-month FDA decision after a complete filing, a submission date for e-cigarette cessation would be the next major catalyst to watch for.
• The Sopharma arbitration, which involves the company that supplies the licence and trademark behind cytisinicline.

This is our first published analysis of Achieve Life Sciences, so there is no earlier outlook to check against.